Comparison of metabolic stability and metabolite identification of 55 ECVAM/ICCVAM validation compounds between human and rat liver homogenates and microsomes - A preliminary analysis

Altex

Volumn 26, Issue 3, 2009, Pages 214-222

  Pelkonen, Olavi ^a   Tolonen, Ari ^b   Rousu, Timo ^b   Tursas, Larissa ^a   Turpeinen, Miia ^a   Hokkanen, Juho ^b   Uusitalo, Jouko ^b   D'Yvoire, Michel Bouvier ^c   Coecke, Sandra ^c  

^a UNIVERSITY OF OULU   (Finland)

^b Novamass Ltd   (Finland)

^c JOINT RESEARCH CENTRE   (Italy)

Author keywords

ECVAM ICCVAM; Human; LC MS techniques; Liver preparations; Metabolic stability; Metabolite formation; Rat; Validation compounds

Indexed keywords

DRUG; PESTICIDE;

ANIMAL; ANIMAL TESTING ALTERNATIVE; ARTICLE; HUMAN; LIVER MICROSOME; METABOLISM; RAT; REPRODUCIBILITY;

ANIMAL TESTING ALTERNATIVES; ANIMALS; HUMANS; MICROSOMES, LIVER; PESTICIDES; PHARMACEUTICAL PREPARATIONS; RATS; REPRODUCIBILITY OF RESULTS;

EID: 73949153084     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.14573/altex.2009.3.214     Document Type: Article

References (11)

1. Boobis, A. R., Kremers, P., Pelkonen, O. and Pithan, K. (editors) (1999). EUR 18569 - European Symposium on the Prediction of Drug Metabolism in Man: Progress and Problems. Luxembourg: Office for Official Publications of the European Communities. 332 pp.
2. Coecke, S., Ahr, H., Blaauboer, B. J. et al. (2006). Metabolism: a Bottleneck in In Vitro Toxicological Test Development: The Report and Recommendations of ECVAM Workshop 54. ATLA 34, 49-84.
3. Pelkonen, O. (2002). Human CYPs: in vivo and clinical aspects. Drug Metab. Rev. 34, 37-46.
4. Pelkonen, O., Baumann, A. and Reichel, A. (2002). Pharmacokinetic Challenges in Drug Discovery. Ernst Schering Research Foundation Workshop 37. Berlin: Springer.
5. Pelkonen, O., Boobis, A. R., Kremers, P. et al. (2001). Interindividual variation of P450 enzymes in vitro and its causes. In G. M. Pacifici and O. Pelkonen (eds.), Variation of Drug metabolism in Humans (269-332). London: Taylor & Francis.
6. Pelkonen, O., Kaltiala, E. H., Larmi, T. K., et al. (1973). Comparison of activities of drug-metabolizing enzymes in human fetal and adult livers. Clin. Pharmacol. Ther. 14, 840-846.
7. Pelkonen, O., Mäenpää, J., Taavitsainen, P. et al. (1998). Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28, 1203-1253.
8. Pelkonen, O. and Raunio, H. (2005). In vitro screening of drug metabolism during drug development: Can we trust the predictions? Exp. Opin. Drug Metab. Toxicol. 1 , 49-60.
9. Pelkonen, O., Turpeinen, M., Uusitalo, J. et al. (2005). Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin. Pharmacol. Toxicol. 96, 167-175.
10. Salonen, J. S., Nyman, L., Boobis, A. R. et al. (2003). Comparative studies on the CYP-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab. Dispos. 31, 1093-1102.
11. Turpeinen, M., Uusitalo, J., Jalonen, J. and Pelkonen, O. (2005). Multiple P450 substrates in a single run: rapid, comprehensive and clinically relevant in vitro interaction and metabolism assay. Eur. J. Pharm. Sci. 24, 123-132.